


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
ASND
Ascendis Pharma A/S
$212.33
Strengths

Upgraded on attractively valued

Outperform the market
Chart
$201.6 (+5.32%)
$198.13 (+7.17%)
$175.71 (+20.84%)
$134.28 (+58.12%)
ASND has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

ASND overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Reported a weak earnings

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future

Outperform the market
![]()
ASND Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
ASND Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayWhat is ASND current stock price?
What are ASND stock strengths?
What is ASND Risk Level?
What is ASND market cap and volume?
What is ASND current Stock IQ?
Should I buy ASND stock right now?
Is ASND a Strong Buy right now?
What does a 'Strong Buy' rating mean for ASND?
What does a 'Strong Sell' rating mean for ASND?
What factors influence ASND's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
ASND
Ascendis Pharma A/S
Current Price
$212.33
Stock Insights
Strengths

Upgraded on attractively valued

Outperform the market

Chart
$201.6 (+5.32%)
$198.13 (+7.17%)
$175.71 (+20.84%)
$134.28 (+58.12%)
ASND Analysts Opinion
ASND Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Reported a weak earnings

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future

Outperform the market
![]()
ASND Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
ASND Street Sentiment is extremely bullish and have positive views on the near-term outlook
ASND has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels.
ASND Latest Analysis
Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026. The United States Food &. Drug Administration (FDA) on Tuesday extended review for ASND) New Drug Application (NDA) for TransCon CNP (navepegritide) for .Achondroplasia is a genetic disorder causing dwarfism characterized by short limbs a normal-sized torso and a large head.It is the most common form of skeletal dysplasia and results from a mutation in the FGFR3 gene which impairs cartilage from turning into bone particu
Today
Is the Market ish or Bearish on Ascendis Pharma AS?. ASND) short interest as a percent of float has risen 3.68% since its last report. According to exchange reported data there are now Short interest is the number of shares that have been sold short but have not yet been covered or closed out. is when a trader sells shares of a company they do not own with the hope that the price will fall. Traders make money from short selling if ...
Wed Nov 26, 2025
Wedbush Reiterates Ascendis Pharma A (ASND) Outperform Recommendation. Fintel reports that on November 18 2025 Wedbush reiterated coverage of Ascendis Pharma A (NasdaqGS:ASND) with a Outperform recommendation. Analyst Price Forecast Suggests 23.21% Upside
Tue Nov 18, 2025
Ascendis Pharma Likely To Report Narrower Q3 Loss. These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call. ASND) will release earnings results for the third quarter after the closing bell on Wednesday Nov. 12.Analysts expect the Hellerup Denmark-based company to report a quarterly loss at 16 cents per share versus a year-ago loss of $1.72 per share. The consensus estimate for Ascendis Pharma'.s quarterly revenue is $210.87 million compared to $57.83 million a year earlier accor
Wed Nov 12, 2025
A Look Ahead: Ascendis Pharmas Earnings Forecast. Ascendis Pharma (NASDAQ:ASND) is preparing to release its quarterly earnings on Wednesday 2025-11-12. Here'.s a brief overview of what investors should keep in mind before the announcement.Analysts expect Ascendis Pharma to report an The market awaits Ascendis Pharma'.s announcement with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.It'.s important for new investors to ...
Tue Nov 11, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
ASND Stock trends
ASND Stock performance
ASND Stock analysis
ASND investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.